Escolha um dos esquemas.
Esquema C: Infecções por bacilos gram-negativos multidrogarresistentes:
Associação:
I.
Polimixina E (Colistina)
4 mg/kg EV de dose inicial (dose máxima: 300 mg de
Colistin Base Activity
- CBA), seguido de 300 mg/dia EV, divididos em 2-3 doses diárias (a partir de 12 horas da dose inicial).
+
II.
Meropeném
1-2 g EV de 8/8 horas, por 7-10 dias.
3.
Glicose hipertônica 50%
200 mL. Distribuir as ampolas entre os frascos utilizados no item 2. Ex.: cinco ampolas em cada frasco, se quatro frascos de 500 mL.
Escolha um dos esquemas.
Esquema D: Infecções por bacilos gram-negativos multidrogarresistentes:
Associação:
I.
Polimixina E (Colistina)
4 mg/kg EV de dose inicial (dose máxima: 300 mg de
Colistin Base Activity
- CBA), seguido de 300 mg/dia EV, divididos em 2-3 doses diárias (a partir de 12 horas da dose inicial).
+
II.
Meropeném
1-2 g EV de 8/8 horas.
Autoria principal: Rafael Silva Duarte (Medicina e Microbiologia).
Brigida M, Saviano A, Petruzziello C, et al. Gut Microbiome Implication and Modulation in the Management of Recurrent Urinary Tract Infection. Pathogens. 2024; 13(12):1028.
Guerriero S, Matteini E, Gross MM, et al. Complicated urinary tract infections: an update of new and developing antibiotics. Expert Opin Pharmacother. 2025; 26(2):167-77.
Hoffman A, Dolezal KA, Powell R. Dysuria: Evaluation and Differential Diagnosis in Adults. Am Fam Physician. 2025; 111(1):37-46.
Lepori M, Braissant O, Bonkat G, et al. Comprehensive analysis of the bacterial spectrum for enhanced clinical insight in microbial ureteral stent colonization, uncomplicated urinary tract infections and catheter-associated urinary tract infections: a principal component analysis-based literature review. World J Urol. 2024; 43(1):29.
Saenz CN, Neugent ML, De Nisco NJ. The Human Urinary Microbiome and Its Potential Role in Urinary Tract Infections. Eur Urol Focus. 2024; 10(6):889-92.
Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, et al. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant
Escherichia coli
Bacteremic Urinary Tract Infections: A Randomized Clinical Trial. JAMA Netw Open. 2022; 5(1):e2137277.
Tamma PD, Heil EL, Justo JA, et al.; Infectious Diseases Society of America. 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clinical Infectious Diseases. 2024; ciae403.
Timm MR, Russell SK, Hultgren SJ. Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics. Nat Rev Microbiol. 2025; 23(2):72-86.